XLR paediatric-optimized MRI workflow to address unmet need in imaging

NewsGuard 100/100 Score

HTX announced today it provided $475,385 in financing to XLR lmaging Inc. (www.xlrimaging.com) through their Technology Acceleration Program. The company is developing a complete paediatric-optimized MRI workflow solution designed to directly address the unique challenges in paediatric imaging while developing high resolution images and reducing scan times.

An essential component of the project is XLR's collaboration with leading luminary sites, such as Boston Children's Hospital and Toronto's Hospital for Sick Children (SickKids), in the design, development, and testing of XLR's pediatric coils.

Enzo Barberi, XLR Imaging founder and CTO, summarizes "We are leveraging our expertise and collaborations with world leading research institutions in neuro MRI to develop a solution that address the unique challenges of paediatric MRI.  Our solution offers unprecedented imaging quality and speed which enables improvements to clinical workflow and the reduction or elimination of Sedation or General Anaesthetics which can increase MRI costs by a factor of 3 to 10.  We are encouraged by our progress to date which has attracted the interest of potential OEM partners, the investment community, and early adopters of the technology".

"Our collaborations with leading paediatric hospitals such as SickKids and Boston Children's have confirmed an unmet clinical need in paediatric MRI. XLR has the right technology assets and clinical partners to develop a truly unique system that is specifically designed for the paediatric patient. The funding from HTX accelerates commercialization of the technology and supports our efforts to gain a critical first mover advantage in this market," states CEO-Designate, Nick Hoffman.

John Soloninka, HTX's President and CEO comments, "OEMs would prefer to partner with a company that has developed a market validated paediatric MRI solution than develop in house. This represents an opportunity for XLR to gain first mover advantage particularly with luminary children hospital sites that will be a critical component of the company's market development strategy."

CHALLENGES WITH CURRENT PAEDIATRIC MRI

  • Paediatric MRI typically involves the use of coils designed for adults which results in poor resolution or inability to image small body structures in children.
  • The paediatric imaging segment has historically been poorly served by the OEMs and there has been little availability of dedicated RF coils and related applications. Yet the number of pediatric MRI cases continues to increase.
  • The use of anaesthetics for pediatric imaging is a growing concern as it increases risk to the patient and introduces workflow and resource challenges associated with need of having an anaesthesiologist available for imaging cases.

BENEFITS OF THE TECHNOLOGY AND TO ONTARIO

  • Lower use of anesthetics improves safety for patients and reduces cost;
  • State-of-the-art imaging provides unprecedented speed and quality; thereby
  • Increasing patient throughput; and
  • Creates a company and related jobs focused on delivering products globally.
Source:

HTX.CA - THE HEALTH TECHNOLOGY EXCHANGE (HTX)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionizing brain tumor treatment: the rise of AI in neuro-oncology